Overcoming the Challenges of CRISPR Screening in Drug Discovery

As drug discovery programs increasingly rely on human genetics to improve target selection and reduce late‑stage attrition, CRISPR screening has emerged as one of the most powerful tools for functional genomics. By enabling systematic interrogation of gene function at scale, CRISPR-based screens allow researchers to move beyond correlative data and directly test how genetic perturbations influence disease‑relevant phenotypes. 

 

Dr. Ben Greulich is an assistant professor of biology at Mercer University, whose work applies CRISPR screening to uncover novel therapeutic strategies in cancer biology. Technology Networks spoke with Greulich to explore how CRISPR screens generate actionable insights for drug discovery, what it takes to optimize a successful screen, where researchers commonly run into trouble, and how recent technological advances may shape the next generation of discovery pipelines. 

Using CRISPR screening to generate actionable drug targets 

How can CRISPR screening provide insights for drug discovery, and what are the main benefits of this approach? 

At its core, CRISPR screening offers a scalable way to connect genes to function. Rather than studying one gene at a time, researchers can perturb thousands of genes in parallel and measure their effects on a phenotype of interest, such as cell survival, signaling output, or drug sensitivity. 

 

“CRISPR screens are great because they allow you to measure the effects of lots of genes on a particular phenotype or process in a relatively high‑throughput manner,” Greulich explained. “Identifying important genes in a phenotype or process of interest allows you to then find or design drugs to target those gene products and manipulate the phenotype in a desired way.” 

 

This functional insight is particularly valuable in drug discovery, where understanding causality is critical. Genetic hits from CRISPR screens can point directly to proteins that drive disease biology, helping teams prioritize targets with stronger mechanistic justification. 

 

Beyond simple gene knockouts, CRISPR screening has also evolved into a versatile platform for probing gene regulation and pathway dynamics. “Traditionally, CRISPR is used to knock out, or delete a gene,” Greulich said. “However, modified Cas9 systems can be used to repress gene expression, activate gene expression, or serve as a fluorescent reporter.” 

 

These expanded modalities—including CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa)—allow researchers to model partial loss‑ or gain‑of‑function effects that may more closely resemble pharmacological intervention. 

 

Applications of CRISPR screens in drug discovery: 

• CRISPR screening links gene function directly to disease‑relevant phenotypes. 

• Functional hits can be translated into druggable targets with stronger biological rationale. 

• Modified Cas9 systems expand screening beyond gene knockout to regulation and reporting. 

Optimizing CRISPR screens for reliable discovery 

What are the most critical parameters when optimizing a CRISPR screen? 

While conceptually powerful, CRISPR screens are technically demanding. One of the first challenges lies in efficiently and reproducibly delivering the CRISPR machinery into cells. 

 

“One of the big limitations for CRISPR applications is the size of the system,” Greulich noted. “For it to work, you need to express the bulky Cas9 protein as well as the specific guide RNAs that target Cas9 to the proper genomic location.” 

 

In most screening workflows, Cas9 is stably expressed in the model system before introducing guide RNAs. This requires careful optimization of viral production, selection of successfully infected cells, and validation of Cas9 expression and activity. “This validated model would then serve as the base of the screen,” Greulich said. 

 

Once Cas9 expression is established, the guide RNA library is introduced. These libraries are typically pooled, containing thousands of different guides targeting distinct genes. This design enables high throughput but introduces a critical experimental variable: multiplicity of infection (MOI), defined as the average number of viral particles infecting each cell. 

 

“It is important to optimize the best, lowest multiplicity of infection, so each cell only receives a single guide RNA,” Greulich explained. “If too much virus is used, you run the risk of altering multiple genes in a single cell, which can confuse the data and make the screen hard to interpret.” 

 

Achieving the right balance ensures sufficient coverage of the library while preserving interpretability—an essential requirement for downstream target validation. 

 

Key parameters for CRISPR screens: 

• Stable Cas9 expression is a foundational requirement for CRISPR screening. 

• Viral delivery and clone validation must be carefully optimized. 

• MOI control is critical to ensure one genetic perturbation per cell. 

Common pitfalls in CRISPR screens for drug discovery

What are some of the most common pitfalls researchers encounter in functional genomics screens? 

Despite careful planning, functional genomics screens frequently fail due to avoidable technical errors. According to Greulich, improper MOI remains the most common and consequential pitfall. 

 

“If you use too little virus, you won't get guide RNAs into many cells, so you won't see many effects. Too much virus though causes multiple changes in a single cell, making it challenging to determine what was actually responsible for the observed effect,” he explained. 

 

This trade‑off highlights the importance of pilot experiments before committing to a full‑scale screen. Titration studies, sequencing‑based quality control, and statistical power calculations all play an essential role in minimizing ambiguity in the final dataset. 

 

More broadly, these pitfalls underscore that CRISPR screening is not simply a plug‑and‑play technology. Experimental rigor at each step determines whether results can meaningfully inform drug discovery decisions. 

 

Mistakes that undermine CRISPR screens and how to mitigate them: 

• Improper MOI can obscure true genetic effects. 

• Pilot optimization is essential before large‑scale screening. 

• Experimental design directly impacts downstream interpretability. 

Scaling CRISPR screening in drug discovery pipelines 

What challenges limit the scalability of CRISPR screening for industrial drug discovery? 

As CRISPR screens move from academic settings into larger discovery pipelines, scalability becomes a central concern. One major challenge is identifying which gene was perturbed in each cell after the screen is complete. 

 

“You can create pure viruses, where each pool of virus only contains a single guide RNA,” Greulich explained. “However, this requires producing a new virus for each and every target to be screened, which can be expensive and very labor-intensive.” 

 

Pooled libraries offer a more scalable alternative, but they shift the burden to sequencing and data analysis. “After the screening, DNA must be harvested from the cells and sequenced to determine the altered gene,” he said. While sequencing costs have dropped dramatically, they remain a limiting factor at very large scales. 

 

Translational relevance presents an additional hurdle. “Cell lines are quite compatible with these screening approaches, but findings in cell lines don‘t always translate to the organismal level,” Greulich noted. In vivo CRISPR screening is possible, but efficiently delivering Cas9 and guide RNAs to the correct tissues—without excessive toxicity—remains a significant challenge. 

 

Other technical limitations include uneven genome coverage, variability in guide RNA performance, and off‑target editing, all of which can complicate hit interpretation. 

 

Difficulties in scaling CRISPR screens: 

• Pooled versus arrayed (one-per-well format) screens involve trade‑offs between scale and clarity. 

• Sequencing and data analysis remain key drivers of cost and complexity. 

• Translating in vitro hits to in vivo systems remains challenging. 

Real‑world impact: CRISPR screening in cancer drug discovery 

How can CRISPR screening directly enable therapeutic insight? 

Greulich pointed to recent work from his own laboratory as an illustration of CRISPR screening’s translational potential. “My lab just published a new paper using a CRISPR screen to identify the gene responsible for regulating TGFBR3 ectodomain shedding and discover a cholesterol‑lowering medication as a potential strategy for reducing TGF-β signaling in cancer.” 

 

Many cancers exhibit dysregulation of the TGF-β pathway, but efforts to inhibit TGF-β directly have had limited success because of TGF-β’s roles in normal tissues. 

 

Greulich and his team instead focused on understanding the regulation of TGF-β. TGFBR3 can promote TGF-β signaling when bound to the cell surface, but when shed from the cell membrane, it acts as an inhibitor. 

The enzymes involved in TGFBR3 shedding remain poorly characterized. A CRISPR knockout screen of proteases revealed several sheddase candidates—PMPCA, GGT7, and PRSS8. Further experiments identified PRSS8 as the most likely TGFBR3 sheddase candidate.  

 

As PRSS8 can be regulated by cholesterol homeostasis pathways, this work provides a new avenue to develop therapeutics for cancers with dysregulated TGF-β signaling. 

 

The study also indicates that statins, FDA-approved drugs used to treat hypercholesterolemia, may be a viable approach to prevent TGF-β-mediated resistance to current therapies. 

 

This type of repurposing opportunity is particularly attractive in drug discovery, where safety profiles and manufacturing pathways are already established. 

 

CRISPR screening’s real-world potential: 

• CRISPR screens can uncover regulators of disease pathways. 

• Genetic hits may point to repurposing opportunities. 

• Functional genomics can accelerate translational insight. 

Emerging technologies shaping the future of CRISPR screening in drug discovery

How might recent advances change what CRISPR screening can deliver? 

Looking ahead, Greulich highlighted advances in sequencing as a major driver of future innovation. “Advances in sequencing technologies, like single‑cell sequencing, Oxford Nanopore sequencing, and PacBio have the potential to advance the analysis of CRISPR screening,” he said. 

 

Single‑cell approaches, in particular, promise to link genetic perturbations to rich phenotypic readouts, such as transcriptional states or lineage trajectories, at unprecedented resolution.

 

Integrating CRISPR screening with single-cell RNA sequencing can help characterize the cellular components altered by the CRISPR screen. Techniques such as ECCITE-seq, Perturb-seq, and CROP-seq expand the types of information obtainable through CRISPR screens, although they face challenges related to technical complexity and limited throughput.

 

As costs continue to fall, these technologies may help address many of the scalability and interpretability challenges that currently limit CRISPR screening in drug discovery. 

 

Technological advances improving CRISPR screen utility: 

• Single‑cell sequencing increases phenotypic resolution. 

• Long‑read technologies improve guide and edit identification. 

• Falling costs may enable broader adoption in discovery pipelines. 

 

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.